SynthesisBMC infectious diseases2025
Otomycosis: a systematic review and meta-analysis of prevalence and causative agents in the era of molecular diagnostics.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Silver nitrate versus clotrimazole for otomycosis: methodological considerations and a TCM perspective.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Isolation and genomic analysis of otomycosis pathogens, and genomics-informed antimicrobial peptide design with potential therapeutic applications.BMC microbiology · 2026Article
- The effect of silver nitrate versus clotrimazole in treatment of otomycosis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Multicenter surveillance of antifungal susceptibility of clinicalMicrobiology spectrum · 2026Article
- Correlation between MIC of econazole nitrate and clinical response in otomycosis.Frontiers in cellular and infection microbiology · 2026Article
- Relative humidity, precipitation, and outpatient visits for clinically diagnosed fungal otitis externa: evidence from a single-center time-series study in Wuxi, eastern China.Frontiers in public health · 2026Article
- Prevalence and Resistance Profiles ofAntibiotics (Basel, Switzerland) · 2025Review
- Epidemiological characteristics and trends in the diagnosis and treatment of fungal otitis externa in children.Translational pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMolecular identification of fungal agents in otomycosis can provide a more accurate diagnosis and differentiation of species compared to conventional morphological methods. Previous reviews mostly relied on studies using conventional methods to explore the prevalence and distribution of otomycosis etiologies. We aim to estimate the prevalence and distribution of causative agents in otomycosis cases confirmed with molecular methods.
methodsWe conducted a systematic search of PubMed, Scopus, Web of Science, and Google Scholar. We selected cross-sectional studies that reported causative agents of otomycosis and used molecular methods for identification of fungi. We appraised the quality of evidence using the JBI Checklist for Prevalence Studies. Clinical and mycological data were collected, and prevalence of otomycosis was estimated by meta-analysis.
resultsTwenty studies reporting 1392 fungal isolates, consisting of 46 species from 11 distinct genera, were included in this review. The prevalence of otomycosis among clinically-suspected patients was 58.3% (95% CI: 41.4-73.5%). Aspergillus (75.8%, 95% CI: 70.3-80.6%) and Candida (15.3%, 95% CI: 8.7- 25.6%) were the most common etiologies. The most frequent Aspergillus species were A. niger (n = 352, 30.9%) and A. tubingensis (n = 270, 23.7%), and the most frequent Candida species were C. parapsilosis (n = 85, 39.7%) and C. albicans (n = 66, 30.8%). The quality of evidence was assessed to be poor in all included studies.
conclusionsOtomycosis is caused by a diverse set of species, predominantly from Aspergillus and Candida genera. Molecular identification techniques provide a more accurate understanding of the distribution of species associated with otomycosis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.